Tanvex BioPharma Inc
TWSE:6541

Watchlist Manager
Tanvex BioPharma Inc Logo
Tanvex BioPharma Inc
TWSE:6541
Watchlist
Price: 63.5 TWD 2.25% Market Closed
Market Cap: 10.4B TWD
Have any thoughts about
Tanvex BioPharma Inc?
Write Note

Tanvex BioPharma Inc
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Tanvex BioPharma Inc
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Tanvex BioPharma Inc
TWSE:6541
Short-Term Debt
NT$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
SSE:688235
Short-Term Debt
ÂĄ4.7B
CAGR 3-Years
31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Polaris Group
TWSE:6550
Short-Term Debt
NT$674.9m
CAGR 3-Years
214%
CAGR 5-Years
9%
CAGR 10-Years
N/A
No Stocks Found

Tanvex BioPharma Inc
Glance View

Market Cap
10.4B TWD
Industry
Biotechnology

Tanvex BioPharma, Inc. operates as clinical stage company, which engages in the research and development, production, and sale of pharmaceutical products. The firm is also engaged in areas of strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing and warehousing, sales and distribution. The Company’s product pipeline includes Neupogen (TX-01), TX-05, TX-04, TX-16, TX-52, and others. The firm offers a vertically integrated manufacturing platform for biopharmaceuticals. By controlling the entire process from research and development (R&D) and cell-line development. The firm is developing and delivering biologic and biosimilar drugs to the people.

Intrinsic Value
1.89 TWD
Overvaluation 97%
Intrinsic Value
Price

See Also

What is Tanvex BioPharma Inc's Short-Term Debt?
Short-Term Debt
0 TWD

Based on the financial report for Sep 30, 2024, Tanvex BioPharma Inc's Short-Term Debt amounts to 0 TWD.

Back to Top